Ikena Oncology (IKNA) Stock Forecast, Price Target & Predictions
IKNA Stock Forecast
Ikena Oncology stock forecast is as follows: an average price target of $1.33 (represents a -21.30% downside from IKNA’s last price of $1.69) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
IKNA Price Target
The average price target for Ikena Oncology (IKNA) is $1.33 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $1.33 to $1.33. This represents a potential -21.30% downside from IKNA's last price of $1.69.
IKNA Analyst Ratings
According to 6 Wall Street analysts, Ikena Oncology's rating consensus is 'Buy'. The analyst rating breakdown for IKNA stock is 0 'Strong Buy' (0.00%), 4 'Buy' (66.67%), 1 'Hold' (16.67%), 1 'Sell' (16.67%), and 0 'Strong Sell' (0.00%).
Ikena Oncology Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 29, 2024 | David Nierengarten | Wedbush | $1.33 | $1.64 | -18.90% | -21.30% |
| May 29, 2024 | David Nierengarten | Wedbush | $2.00 | $1.33 | 50.38% | 18.34% |
The latest Ikena Oncology stock forecast, released on May 29, 2024 by David Nierengarten from Wedbush, set a price target of $1.33, which represents a -18.90% decrease from the stock price at the time of the forecast ($1.64), and a -21.30% decrease from IKNA last price ($1.69).
Ikena Oncology Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $1.67 |
| Last Closing Price | $1.69 | $1.69 | $1.69 |
| Upside/Downside | -100.00% | -100.00% | -1.18% |
In the current month, the average price target of Ikena Oncology stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Ikena Oncology's last price of $1.69. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 29, 2024 | William Blair | Outperform | Outperform | Hold |
| May 29, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 29, 2024 | Wells Fargo | - | Underweight | Downgrade |
| May 29, 2024 | Wedbush | Outperform | Neutral | Downgrade |
| May 29, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 14, 2024 | Wedbush | Buy | Outperform | Initialise |
| Mar 19, 2024 | Wedbush | Buy | Buy | Hold |
| Mar 19, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Jan 19, 2024 | Wedbush | Outperform | Outperform | Hold |
| Sep 22, 2023 | Wedbush | - | Outperform | Initialise |
Ikena Oncology's last stock rating was published by William Blair on May 29, 2024. The company gave IKNA a "Outperform" rating, the same as its previous rate.
Ikena Oncology Financial Forecast
Ikena Oncology Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $659.00K | - | - | $5.31M | $5.45M | $6.40M | $382.00K | $3.38M | $20.22M | $3.75M | $3.55M | $3.47M |
| Avg Forecast | - | - | - | - | $1.25M | $1.25M | $1.25M | $1.25M | $1.25M | $1.25M | $875.00K | $2.33M | $2.44M | $2.84M | $3.85M | $4.61M | $6.02M | $4.32M | $3.87M | $4.57M | $4.79M | $4.05M | $3.93M | $3.97M |
| High Forecast | - | - | - | - | $1.25M | $1.25M | $1.25M | $1.25M | $1.25M | $1.25M | $875.00K | $2.33M | $5.10M | $2.84M | $3.85M | $4.61M | $6.02M | $4.32M | $3.87M | $4.57M | $4.79M | $4.05M | $3.93M | $3.97M |
| Low Forecast | - | - | - | - | $1.25M | $1.25M | $1.25M | $1.25M | $1.25M | $1.25M | $875.00K | $2.33M | $673.39K | $2.84M | $3.85M | $4.61M | $6.02M | $4.32M | $3.87M | $4.57M | $4.79M | $4.05M | $3.93M | $3.97M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.27% | - | - | 1.15% | 0.91% | 1.48% | 0.10% | 0.74% | 4.22% | 0.92% | 0.90% | 0.88% |
Ikena Oncology's average Quarter revenue forecast for Mar 24 based on 2 analysts is $2.33M, with a low forecast of $2.33M, and a high forecast of $2.33M. IKNA's average Quarter revenue forecast represents a 254.07% increase compared to the company's last Quarter revenue of $659.00K (Dec 23).
Ikena Oncology EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-21.60M | $-19.50M | $-18.49M | $-15.28M | $-14.90M | $-17.66M | $-20.80M | $-16.78M | $2.96M | $-14.94M | $-11.97M | $-9.63M |
| Avg Forecast | - | - | - | - | $-1.25M | $-1.25M | $-1.25M | $-1.25M | $-1.25M | $-1.25M | $-875.00K | $-2.33M | $-2.44M | $-2.84M | $-3.85M | $-4.61M | $-6.02M | $-14.31M | $-3.87M | $-14.52M | $-4.79M | $-4.05M | $-3.93M | $-14.78M |
| High Forecast | - | - | - | - | $-1.25M | $-1.25M | $-1.25M | $-1.25M | $-1.25M | $-1.25M | $-875.00K | $-2.33M | $-673.39K | $-2.84M | $-3.85M | $-4.61M | $-6.02M | $-11.44M | $-3.87M | $-11.62M | $-4.79M | $-4.05M | $-3.93M | $-11.82M |
| Low Forecast | - | - | - | - | $-1.25M | $-1.25M | $-1.25M | $-1.25M | $-1.25M | $-1.25M | $-875.00K | $-2.33M | $-5.10M | $-2.84M | $-3.85M | $-4.61M | $-6.02M | $-17.17M | $-3.87M | $-17.43M | $-4.79M | $-4.05M | $-3.93M | $-17.74M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 8.86% | 6.87% | 4.80% | 3.31% | 2.48% | 1.23% | 5.37% | 1.16% | -0.62% | 3.69% | 3.04% | 0.65% |
1 analysts predict IKNA's average Quarter EBITDA for Mar 22 to be $-14.52M, with a high of $-11.62M and a low of $-17.43M. This is -590.68% lower than Ikena Oncology's previous annual EBITDA (Dec 21) of $2.96M.
Ikena Oncology Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-19.49M | $-17.34M | $-17.11M | $-12.92M | $-13.08M | $-16.80M | $-20.03M | $-16.72M | $2.80M | $-14.52M | $-12.68M | $-9.72M |
| Avg Forecast | $-6.61M | $-6.61M | $-6.60M | $-7.43M | $-9.80M | $-9.94M | $-9.93M | $-11.13M | $-11.89M | $-12.24M | $-16.72M | $-19.19M | $-20.09M | $-20.78M | $-22.87M | $-22.52M | $-7.04M | $-13.90M | $-23.56M | $-14.83M | $-24.72M | $-20.27M | $-17.25M | $-14.92M |
| High Forecast | $-6.61M | $-6.61M | $-6.60M | $-7.43M | $-9.80M | $-9.94M | $-9.93M | $-11.13M | $-11.89M | $-9.89M | $-16.72M | $-19.19M | $-16.82M | $-20.78M | $-22.87M | $-22.52M | $-7.04M | $-11.12M | $-23.56M | $-11.87M | $-24.72M | $-20.27M | $-17.25M | $-11.93M |
| Low Forecast | $-6.61M | $-6.61M | $-6.60M | $-7.43M | $-9.80M | $-9.94M | $-9.93M | $-11.13M | $-11.89M | $-15.54M | $-16.72M | $-19.19M | $-26.62M | $-20.78M | $-22.87M | $-22.52M | $-7.04M | $-16.68M | $-23.56M | $-17.80M | $-24.72M | $-20.27M | $-17.25M | $-17.90M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.97% | 0.83% | 0.75% | 0.57% | 1.86% | 1.21% | 0.85% | 1.13% | -0.11% | 0.72% | 0.74% | 0.65% |
Ikena Oncology's average Quarter net income forecast for Mar 22 is $-14.83M, with a range of $-17.80M to $-11.87M. IKNA's average Quarter net income forecast represents a -630.37% decrease compared to the company's last Quarter net income of $2.80M (Dec 21).
Ikena Oncology SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $8.29M | $6.03M | $5.32M | $5.28M | $4.92M | $5.43M | $5.84M | $6.00M | $5.09M | $4.89M | $4.86M | $3.17M |
| Avg Forecast | - | - | - | - | $1.55M | $1.55M | $1.55M | $1.55M | $1.55M | $1.55M | $1.09M | $2.90M | $3.03M | $3.53M | $4.79M | $5.74M | $7.48M | $5.38M | $4.82M | $5.68M | $5.95M | $5.04M | $4.89M | $4.93M |
| High Forecast | - | - | - | - | $1.55M | $1.55M | $1.55M | $1.55M | $1.55M | $1.55M | $1.09M | $2.90M | $6.35M | $3.53M | $4.79M | $5.74M | $7.48M | $5.38M | $4.82M | $5.68M | $5.95M | $5.04M | $4.89M | $4.93M |
| Low Forecast | - | - | - | - | $1.55M | $1.55M | $1.55M | $1.55M | $1.55M | $1.55M | $1.09M | $2.90M | $837.65K | $3.53M | $4.79M | $5.74M | $7.48M | $5.38M | $4.82M | $5.68M | $5.95M | $5.04M | $4.89M | $4.93M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 2.73% | 1.71% | 1.11% | 0.92% | 0.66% | 1.01% | 1.21% | 1.06% | 0.85% | 0.97% | 0.99% | 0.64% |
Ikena Oncology's average Quarter SG&A projection for Mar 24 is $2.90M, based on 2 Wall Street analysts, with a range of $2.90M to $2.90M. The forecast indicates a -65.00% fall compared to IKNA last annual SG&A of $8.29M (Dec 23).
Ikena Oncology EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.41 | $-0.00 | $-0.44 | $-0.36 | $-0.36 | $-0.46 | $-0.55 | $-0.46 | $0.08 | $-0.40 | $-0.35 | $-2.52 |
| Avg Forecast | $-0.14 | $-0.14 | $-0.14 | $-0.15 | $-0.20 | $-0.21 | $-0.21 | $-0.23 | $-0.25 | $-0.25 | $-0.35 | $-0.40 | $-0.42 | $-0.43 | $-0.47 | $-0.47 | $-0.15 | $-0.49 | $-0.49 | $-0.42 | $-0.51 | $-0.42 | $-0.36 | $-0.87 |
| High Forecast | $-0.14 | $-0.14 | $-0.14 | $-0.15 | $-0.20 | $-0.21 | $-0.21 | $-0.23 | $-0.25 | $-0.20 | $-0.35 | $-0.40 | $-0.35 | $-0.43 | $-0.47 | $-0.47 | $-0.15 | $-0.49 | $-0.49 | $-0.42 | $-0.51 | $-0.42 | $-0.36 | $-0.87 |
| Low Forecast | $-0.14 | $-0.14 | $-0.14 | $-0.15 | $-0.20 | $-0.21 | $-0.21 | $-0.23 | $-0.25 | $-0.32 | $-0.35 | $-0.40 | $-0.55 | $-0.43 | $-0.47 | $-0.47 | $-0.15 | $-0.49 | $-0.49 | $-0.42 | $-0.51 | $-0.42 | $-0.36 | $-0.87 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.99% | 0.00% | 0.93% | 0.77% | 2.47% | 0.93% | 1.13% | 1.10% | -0.15% | 0.95% | 0.98% | 2.89% |
According to 1 Wall Street analysts, Ikena Oncology's projected average Quarter EPS for Mar 22 is $-0.42, with a low estimate of $-0.42 and a high estimate of $-0.42. This represents a -636.05% decrease compared to IKNA previous annual EPS of $0.08 (Dec 21).
Ikena Oncology Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XLO | Xilio Therapeutics | $0.82 | $7.00 | 753.66% | Buy |
| AVTE | Aerovate Therapeutics | $1.90 | $13.00 | 584.21% | Hold |
| HOWL | Werewolf Therapeutics | $2.34 | $12.00 | 412.82% | Buy |
| STTK | Shattuck Labs | $3.81 | $12.00 | 214.96% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| RZLT | Rezolute | $5.25 | $13.00 | 147.62% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| CELC | Celcuity | $14.98 | $31.50 | 110.28% | Buy |
| FHTX | Foghorn Therapeutics | $9.72 | $18.00 | 85.19% | Buy |
| DSGN | Design Therapeutics | $5.54 | $9.67 | 74.55% | Buy |
| ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
| NRIX | Nurix Therapeutics | $24.80 | $27.57 | 11.17% | Buy |
| KYMR | Kymera Therapeutics | $46.08 | $51.10 | 10.89% | Buy |
| IKNA | Ikena Oncology | $1.69 | $1.33 | -21.30% | Buy |
IKNA Forecast FAQ
Is Ikena Oncology a good buy?
Yes, according to 6 Wall Street analysts, Ikena Oncology (IKNA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 66.67% of IKNA's total ratings.
What is IKNA's price target?
Ikena Oncology (IKNA) average price target is $1.33 with a range of $1.33 to $1.33, implying a -21.30% from its last price of $1.69. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Ikena Oncology stock go up soon?
According to Wall Street analysts' prediction for IKNA stock, the company can go down by -21.30% (from the last price of $1.69 to the average price target of $1.33), down by -21.30% based on the highest stock price target, and down by -21.30% based on the lowest stock price target.
Can Ikena Oncology stock reach $3?
IKNA's average twelve months analyst stock price target of $1.33 does not support the claim that Ikena Oncology can reach $3 in the near future.
What are Ikena Oncology's analysts' financial forecasts?
Ikena Oncology's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $5M (high $5M, low $5M), average EBITDA is $-5M (high $-5M, low $-5M), average net income is $-40.796M (high $-40.796M, low $-40.796M), average SG&A $6.22M (high $6.22M, low $6.22M), and average EPS is $-0.845 (high $-0.845, low $-0.845). IKNA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-27.251M (high $-27.251M, low $-27.251M), average SG&A $0 (high $0, low $0), and average EPS is $-0.565 (high $-0.565, low $-0.565).
Did the IKNA's actual financial results beat the analysts' financial forecasts?
Based on Ikena Oncology's last annual report (Dec 2022), the company's revenue was $15.62M, which missed the average analysts forecast of $18.78M by -16.85%. Apple's EBITDA was $-70.153M, beating the average prediction of $-38.72M by 81.18%. The company's net income was $-66.626M, beating the average estimation of $-59.336M by 12.29%. Apple's SG&A was $22.2M, missing the average forecast of $23.36M by -4.98%. Lastly, the company's EPS was $-1.84, beating the average prediction of $-1.546 by 19.05%. In terms of the last quarterly report (Dec 2023), Ikena Oncology's revenue was $659K, missing the average analysts' forecast of $2.44M by -72.98%. The company's EBITDA was $-21.603M, beating the average prediction of $-2.438M by 785.91%. Ikena Oncology's net income was $-19.489M, missing the average estimation of $-20.085M by -2.97%. The company's SG&A was $8.29M, beating the average forecast of $3.03M by 173.40%. Lastly, the company's EPS was $-0.41, missing the average prediction of $-0.416 by -1.49%